Why the study?
Patients with type 1 diabetes commonly use either SMBG or CGM, motivating the development of an adaptive basal-bolus algorithm that supports inputs from either device.
Does an adaptive basal-bolus algorithm based on reinforcement learning achieve comparable glucose control using either SMBG or CGM inputs in simulated adults with type 1 diabetes?
Does an adaptive basal-bolus algorithm based on reinforcement learning achieve comparable glucose control using either SMBG or CGM inputs in simulated adults with type 1 diabetes?
An AI-based adaptive basal-bolus algorithm can provide personalized insulin optimization and achieve glucose control independent of the type of glucose monitoring technology in an in silico model.
ABBA improved TIR in silico for T1D/T2D on MDI; leaves open need for human trials before any practice change.
Self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) are commonly used by type 1 diabetes (T1D) patients to measure glucose concentrations. The proposed adaptive basal-bolus algorithm (ABBA) supports inputs from either SMBG or CGM devices to provide personalised suggestions for the daily basal rate and prandial insulin doses on the basis of the patients' glucose level on the previous day. The ABBA is based on reinforcement learning, a type of artificial intelligence, and was validated in silico with an FDA-accepted population of 100 adults under different realistic scenarios lasting three simulated months. The scenarios involve three main meals and one bedtime snack per day, along with different variabilities and uncertainties for insulin sensitivity, mealtime, carbohydrate amount, and glucose measurement time. The results indicate that the proposed approach achieves comparable performance with CGM or SMBG as input signals, without influencing the total daily insulin dose. The results are a promising indication that AI algorithmic approaches can provide personalised adaptive insulin optimization and achieve glucose control-independent of the type of glucose monitoring technology.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: